USA v. Abbott Laboratories et al

  1. May 18, 2016

    No New Trial For Abbott Whistleblower In $219M Stent Row

    The whistleblower who in April lost a $219 million suit against Abbott Laboratories over allegedly improperly marketed bile duct stents won't get a new trial, a Texas federal judge ruled on Wednesday, finding that nothing in the proceeding led to an unfair trial.

  2. May 06, 2016

    Abbott Whistleblower Seeks New Trial In $219M Stent Row

    The whistleblower who accused Abbott Laboratories of improperly marketing bile duct stents for off-label use asked a Texas federal judge Friday to grant a new trial after a jury in April cleared the medical device maker in a False Claims Act suit that sought $219 million in damages.

  3. April 08, 2016

    Health Fraud Defense Attys Riding High As Wins Pile Up

    A jury verdict for Abbott Laboratories in a $200 million False Claims Act trial involving off-label marketing joins a string of recent defense wins in high-profile health fraud cases and suggests that the tide is turning after years of harsh financial penalties, attorneys say.

  4. April 07, 2016

    Abbott Prevails In $219M Whistleblower FCA Trial

    A Texas federal jury on Thursday cleared Abbott Laboratories of accusations it improperly marketed bile duct stents for off-label uses, in a whistleblower False Claims Act case that had sought $219 million in damages.

  5. April 07, 2016

    Ex-Abbott Rep Says Profits Trumped Safety In $219M FCA Trial

    A former Abbott Laboratories sales-director-turned-whistleblower asked a Texas federal jury Thursday to find that the medical device manufacturer caused the submission of more than 35,000 false Medicare and Medicaid claims, costing the U.S. government more than $219 million.

  6. April 01, 2016

    Abbott Whistleblower Blasts Directed Verdict Bid

    A former Abbott Laboratories sales director fired back in Texas federal court Friday against the company's bid for a judge to shut down his False Claims Act suit, saying the jury heard enough evidence to hold Abbott responsible for $219 million in fraudulent Medicare claims.

  7. March 25, 2016

    Abbott Whistleblower Defends $219M FCA Claim To Jury

    A former Abbott Laboratories sales-director-turned-whistleblower told a Texas federal jury Friday he reported the company to federal investigators in an earnest belief it was best for the U.S. health care system, during a $219 million trial over allegedly false Medicare claims.

  8. March 22, 2016

    Abbott Faces $219M FCA Trial Over Off-Label Stent Marketing

    A former Abbott Laboratories sales director on Tuesday told a Texas federal jury the company charged Medicare $219 million for unauthorized uses of its stents, as a decade-old False Claims Act whistleblower case kicked off a three-week trial.

  9. January 13, 2016

    Abbott Asks For Reconsideration To End Stent FCA Suit

    Abbott Laboratories asked a Texas federal judge Tuesday to rethink her decision forcing the company to face a whistleblower's False Claims Act lawsuit alleging it marketed stents for off-label uses, arguing that it need only show its marketing was "objectively reasonable" to evade the claims.

  10. January 07, 2016

    Abbott, Whistleblower Can't End Stent False Claims Suit

    A Texas federal judge on Thursday denied bids by both Abbott Laboratories and a former employee who accuses the company of violating the False Claims Act by marketing stents for off-label uses to quickly end the suit, finding that too many questions about whether the devices qualified for Medicare billing remained.